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Abstract
The A2 adenosine receptors play an important role, among others, in the regulation of
inflammatory process and glucose homeostasis in diabetes and obesity. Thus, the
presented project evaluated of influence of the selective antagonist of A2A adenosine recep-
tor—KD-64 as compared to the known non-selective antagonist—caffeine on these two par-
ticular processes. Two different inflammation models were induced namely local and
systemic inflammation. Obesity was induced in mice by high-fat diet and the tested com-
pounds (KD-64 and caffeine) were administrated for 21 days. KD-64 showed anti-inflamma-
tory effect in both tested inflammation models and administered at the same dose as
ketoprofen exerted stronger effect than this reference compound. Elevated levels of IL-6
and TNF-α observed in obese control mice were significantly lowered by the administration
of KD-64 and were similar to the values observed in control non-obese mice. Interestingly,
caffeine increased the levels of these parameters. In contrast to caffeine which had no influ-
ence on AlaT activity, KD-64 administration significantly lowered AlaT activity in the obese
mice. Although, contrary to caffeine, KD-64 did not reduce diet-induced obesity in mice, it
improved glucose tolerance. Thus, the activity of the selective adenosine A2A receptor
antagonist was quite different from that of the non-selective.
Introduction
Obesity is defined as over-storage of lipids in adipose tissue that occurs when the amount of
supplied energy significantly exceeds its consumption by the body [1]. Currently, it is an
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extremely important civilization problem, since obesity is considered a risk factor for cardio-
vascular diseases (e.g. ischemic heart disease, hypertension, heart failure, stroke), diabetes, dys-
lipidemia, autoimmune diseases and even cancer [2]. The reasons for overweight (and obesity)
are numerous and varied. Genetic, environmental and/or social factors as well as the hormonal
status of the body play the major role in its pathogenesis [3]. According to the current theory,
development of obesity, associated with adipocyte hypertrophy and hyperplasia, is connected
not only with disturbances in the secretory function of the fat tissue, but also with increased
inflammatory activation of adipocytes, release of pro-inflammatory cytokines and dysregula-
tion of adipokine secretion [4, 5, 6, 7]. An increase in the levels of pro-inflammatory cytokines
and proteins such as interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), leptin or C-
reactive protein (CRP) in both blood and adipose tissue itself was observed as obesity pro-
gressed. On the other hand, reduced levels of anti-inflammatory factors for instance adiponec-
tin [8] as well as various changes (increase or decrease) in IL-10 levels together with the mostly
unchanged levels of IL-8 [9, 10] seem to be also relevant. Until now, the mechanism triggering
inflammatory activation of adipose tissue has not been clearly defined. Different theories point
to the role of hypoxia of adipocytes [11], cellular stress during obesity development [12], and
elevated glucose level, all generating large amounts of free oxygen radicals in adipocytes and
stimulating pro-inflammatory cytokines secretion [13, 14].
Pharmacological treatment of obesity remains an unresolved problem. The role of adeno-
sine receptor signalling in the development and progression of numerous diseases has been
emphasized for years [15]. Adenosine is an endogenous purine nucleoside that participates in
the development of obesity [16]. It works through adenosine receptors such as A1, A2A, A2B
and A3 that differ in their pharmacological profile (including affinity for adenosine), tissue
localization and the system of second order messengers. Adenosine receptors are widely
expressed in organs and tissues involved in metabolism regulation such as liver, pancreas, adi-
pose tissue and muscles, moreover its presence on immune cells [17], points to their significant
role in the inflammatory processes. Since all of these receptors are engaged in glucose homeo-
stasis, adipogenesis, insulin resistance, inflammation and thermogenesis, treatment with spe-
cific agonist and/or antagonists could normalize several mechanisms involved in
pathophysiology of obesity [18].
The A2A receptor being the most abundant adenosine receptor in human and murine white
and brown adipose tissue, as well as on immune cells and organs has become a potential target
for obesity studies [17, 19]. Data indicate that adenosine signalling via A2A is required for acti-
vation of brown adipose tissue and protects mice from diet-induced obesity [20]. It has been
also demonstrated that A2A receptor knockout mice exhibit impaired thermogenesis, oxygen
consumption, and lipolysis [21]. Moreover, Csóka et al., (2017) observed the reduced food
intake in such mice and consequently a lower body mass as compared to control animals [22].
A strong functional interaction between the dopamine D2 and adenosine A2A receptors [23]
has been further discovered and a blockade of adenosine A2A receptor can even mimic the
action of D2 agonists [24]. Since dopamine is known to be an important regulator of energy
expenditure [25, 26] and food intake [27] reduced dopamine signal transduction may give rise
to overeating and decreased energy consumption, both of which contribute to the positive
energy balance seen in obesity [28].
The adenosine A2A receptor is predominantly expressed on inflammatory cells, including
neutrophils, mast cells, macrophages, monocytes, and platelets [29] and in many animal stud-
ies it has been demonstrated that its activation reduced inflammatory processes [29, 30] and
improved molecular markers of inflammation. On the other hand, it has been shown that the
direct local injection of the selective A2A receptor antagonist ZM 241385 (from the group of
non xanthine adenosine receptors antagonists) in carrageenan-induced inflammatory
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hyperalgesia reduced inflammatory hypersensitivity suggesting that activation of peripheral
adenosine A2A receptors during inflammation is associated with mechanical hyperalgesia [31].
Zygmunt et al., (2015) presented the series of A2A adenosine receptor ligands, a group of ary-
lalkyl pyrimido [2,1-f]-purinediones (Fig 1A) with significant anti-inflammatory activity in
carrageenan-induced paw edema model. These compounds—annelated xanthine derivatives
—have similar structure to KD-64 –ligand (Fig 1B) we have used in the presented study [32].
For comparison purposes caffeine (1,3,7-trimethyl xanthine) (Fig 1C) was chosen, a non-
selective A1 and A2A adenosine antagonist and the most popular and well-studied methylxan-
tine which has been reported as thermogenic and lipolysis stimulator leading to fat oxidation
in adipocytes and release of glycerol and fatty acids to the bloodstream [33, 34]. Moreover, caf-
feine modulates glucose metabolism and increases energy expenditure, as well as has impact
on [35] body fat reduction [36] and weight loss [37] mostly as adjuwant agent [38, 39] espe-
cially during physical exercise or when administered simultaneously with the calorie restric-
tion diets [40, 41].
While non-selective adenosine A1 and A2A receptor antagonists such as caffeine are well
investigated in obesity-related mechanisms, the results of studies on selective A2A receptor
antagonists are still inconsistent, therefore we have chosen for our experiments a selective A2A
receptor antagonist, designated as KD-64, with significant selectivity over other adenosine
receptors (Ki [μM] values are 0.24, > 25, > 10 and> 10 for A2A, A1, A2B and A3 receptors,
respectively) [42].
In the first part of our research we have estimated the effect of KD-64 on the inflammation
in the carrageenan or zymosan induced models of inflammation. Further, in a diet-induced
Fig 1. Chemical scheme of annelated xanthine derivatives (A), structure of compound KD-64 (B), structure of caffeine (C).
https://doi.org/10.1371/journal.pone.0229806.g001
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mice obesity model, we have confirmed the development of inflammation, and compared the
effects of investigated compound and caffeine, i.e. selective and non-selective A2A receptor
antagonists, on the primary metabolic variables.
Materials and methods
Animals
Adult (six-week old) male Albino Swiss mice, CD-1, weighing 25–30 g were used in the
inflammatory models and estimation of locomotor activity and adult (six-week old) female
Albino Swiss mice, CD-1, weighing 19–22 g were used in the model of obesity. The animals
were obtained from the Animal House of the Faculty of Pharmacy of the Jagiellonian Univer-
sity Medical College. Animals were kept in environmentally controlled rooms, in standard
cages lit by an artificial light for 12h each day. They had free access to food and water, except
for the time of the acute experiment. The randomly established experimental groups consisted
of 8 mice. All animal care and experimental procedures were carried out in accordance with
European Union and Polish legislation acts concerning animal experimentation, and were
approved by the Local Ethics Committee at the Jagiellonian University in Cracow, Poland
(Permission No: 256/2015 and 55/2017).
During the experiments, when possible, steps were taken to minimize animal suffering and
distress. Unfortunately, in the anti-inflammatory studies, it was not possible to administer any
anaesthetics and analgesics since they would interfere with the tests, however the animals were
not isolated individually to avoid developing stress. In the studies of anti-obesity properties
efforts were made to create the safe and stress-free conditions for animals so that stress would
not affect the results of experiments. During the induction of obesity, only two people respon-
sible for the subsequent administration of the investigated compounds, were allowed to handle
the animals. After experiment mice were killed by decapitation that is considered to be the
most humane method of mouse euthanasia.
Drugs, chemical reagents and other materials
Ketoprofen was used as standard anti-inflammatory compound and was purchased from
Sigma-Aldrich (Poland). Carrageen was purchased from FCM Corporation (USA), Zymozan
A and Evans blue from Sigma-Aldrich (Poland), Caffeine (used as standard in obese model)
was purchased from Alfa-Aesar (Poland). KD-64—(1,3-dimethyl-9-((1r,4r)-4-methylcyclo-
hexyl-6,7,8,9-tetrahydropyrimido[2,1-f]purine-2,3(1H,3H)-dione) (Fig 1B) [43] was synthe-
sized in the Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy,
Jagiellonian University Medical College, Cracow, Poland. NMR and LC-MS techniques
assessed identity and purity of final product. In all experiments ketoprofen, caffeine or KD-64
were administered as suspensions in 1% Tween 80 in sterile water for injection.
Inflammation models
Carrageenan-induced edema model. To induce inflammation, 0.1 ml of 1% carrageenan
solution in water was injected into the hind paw subplantar tissue of mice, according to the
modified method of C. A. Winter and P. Lence [44, 45], as described previously [46]. The
development of paw edema was measured with a plethysmometr (Plethysmometr 7140, Ugo
Basile). Prior to the administration of the tested substances (KD-64 or ketoprofen), paw diam-
eters were measured and data were recorded for further comparison. The KD-64 compound
was administered at the doses of 1, 5 or 10 mg/kg, intraperitoneal (ip), prior to carrageenan
injection, similarly ketoprofen (reference standard) was administered at the dose of 5 mg/kg
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[47]. 1% Tween 80 (vehicle) was administered by the same route to the control group (it had
no effect on edema). Results were presented as changes in the hind paw volume 3 h after carra-
geenan administration. Immediately, after measurement mice were administrated 2500 units/
mice of heparin ip and 20 minutes later sacrificed by decapitation. Blood was collected to the
Eppendorf tubes and centrifuged at 600 x g (15 min, 4˚C) in order to obtain plasma used for
the determination of CRP levels.
Zymosan A induced peritoneal inflammation. Peritoneal inflammation was induced as
described previously [48]. Zymosan A was freshly prepared (2 mg/ml) in sterile 0.9% NaCl
and 30 minutes after ip injection of the investigated compounds (KD-64 or ketoprofen at the
dose of 5 mg/kg), zymosan A was injected via the same route. Four hours later the animals
were killed by decapitation and blood was collected into a heparin-containing tubes. After cen-
trifugation mice plasma was stored for the further measurements of the CRP levels. The perito-
neal cavity was lavaged with 1.5 ml of PBS and after 30s of gentle manual massaging the
exudates were retrieved. Cells were counted using an optical microscope (DM1000, Leica) and
Bürker hemocytometer following staining with Turk’s solution.
Vascular permeability. In the control studies Evans blue was suspended in the saline (10
mg/ml) and injected intravenously (iv) into the caudal vein, which was immediately followed
by ip injection of zymosan A. Thirty minutes later the animals were killed by decapitation and
their peritoneal cavities were lavaged with 1.5 ml of saline as described above. The lavage fluid
was centrifuged and the absorbance of the supernatant was measured at 620 nm in order to
assess vascular permeability by peritoneal leakage of iv injected Evans blue as described previ-
ously [48]. In the subsequent experiments KD-64, ketoprofen (reference standard) both at the
dose of 5 mg/kg or vehicle (administered sc, control group) were injected ip 30 min before
Evans blue and zymosan A. Further procedures were the same as in the control group.
Locomotor activity
The locomotor activity was recorded with an Opto M3 multichannel activity monitor (Multi-
Device Software v1.3, Columbus Instruments, USA). It was evaluated as the distance travelled
by the animals while attempting to climb upward [49]. After ip administration of KD-64 com-
pound at the doses of 1, 5 or 10 mg/kg, each mouse was placed in a cage for a 30 minutes’
habituation period. After that time the number of crossings of photo beams was measured for
20 minutes.
Obesity study
Metabolic disturbance induced with a high-fat/sucrose diet and its influence on body
weight and spontaneous activity. Mice were fed on high-fat diet consisting of 40% fat blend
(Labofeed B with 40% lard, Morawski Feed Manufacturer, Poland) for 15 weeks, water and
30% sucrose solution were available ad libitum [50, 51]. Control mice were fed on a standard
diet (Labofeed B, Morawski Feed Manufacturer, Poland) and drank water only. After 12
weeks, mice with obesity were randomly divided into three equal groups that had the same
mean body weight and were treated ip with tested compounds at the following doses: KD-64 5
mg/kg b.w./day or caffeine 50 mg/kg b.w./day and control group: 1% Tween 80 (vehicle) 0.35
ml/kg (fat/sugar diet + vehicle = obesity control group) once daily between 9:00 and 10:00 AM
for 21 days. Control mice (control without obesity) were maintained on a standard diet, with
ip administration of 1% Tween 80, 0.35 ml/kg (standard diet + vehicle = control group). Ani-
mals always had free access to feed, water and sucrose. After experiment mice were killed by
decapitation and plasma was harvested to determine levels of TNF-α, IL-6 and activity of ala-
nine aminotransferase (AlaT).
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High-fat feed composition: protein–193 g, fat (lard)–408 g, fiber–28.1 g, crude ash–43.6 g,
calcium–9.43 g, phosphorus–5.99 g, sodium–1.76 g, sugar–76 g, magnesium–1.72 g, potas-
sium–7.62 g, manganese–48.7 mg, iodine–216 mg, copper–10.8 mg, iron–125 mg, zinc–61.3
mg, cobalt–0.253 mg, selenium–0.304 mg, vitamin A–15000 units, vitamin D3–1000 units,
vitamin E–95.3 mg, vitamin K3–3.0 mg, vitamin B1–8.06 mg, vitamin B2–6.47 mg, vitamin
B6–10.3 mg, vitamin B12–0.051 mg, folic acid–2.05 mg, nicotinic acid–73.8 mg, pantothenic
acid–19.4 mg, choline–1578 mg, lysine 9.0 g, methionine + cysteine 6.3 g, tryptophan 2.0 g,
threonine 6.0 g, isoleucine 6.0 g, leucine 12.0 g, valine 8.0 g, histidine 4.0 g, arginine 10.0 g,
phenylalanine 7.0 g, tyrosine 5.5 g, betaine 17.0 g.
Standard feed composition: protein–175 g, fat–35 g, fiber–70 g, crude ash–32 g, starch–
330 g, calcium–9.5 g, phosphorus–7.5 g, magnesium–3 g, potassium–7.5 g, sodium–1.9 g,
manganese–50 mg, iodine–144 mg, sulfur–1,9 g, zinc–50 mg, copper–11 mg, iodine–200
mg, selenium–0.4 mg, vitamin A–12000 units, vitamin D3–800 units, vitamin E–78 mg, vita-
min K3–2.4 mg, vitamin B1–8 mg, vitamin B2–7 mg, vitamin B6–11 mg, vitamin B12–0.042
mg, folic acid–25 mg, nicotinic acid–94 mg, pantothenic acid–25 mg, choline–1900 mg,
lysine 9.0 g, methionine + cysteine 6.3 g, tryptophan 2.0 g, threonine 6.0 g, isoleucine 6.0 g,
leucine 12.0 g, valine 8.0 g, histidine 4.0 g, arginine 10.0 g, phenylalanine 7.0 g, tyrosine 5.5
g, betaine 17.0 g.
The high-fat diet contained 550 kcal and the standard diet 280 kcal per 100 g.
The spontaneous activity of mice was measured on the 1st and 21st day of the treatment
with a special RFID-system—TraffiCage (TSE-Systems, Germany). The animals were subcuta-
neously implanted with a radio-frequency identificator (RFID), which enabled to count the
presence and time spent in different areas of the cage. The obtained data was grouped using an
appropriate computer program [49].
Biochemical analysis
Glucose tolerance test. The glucose tolerance test was performed at the beginning of 16th
week. After twenty administrations of the tested compounds (KD-64 or caffeine), food and
sucrose were discontinued for 20h and then glucose tolerance was tested. Glucose (1g/kg b.w.)
was administrated ip [50, 51] and blood samples were taken from the tail vein at the time
points: 0 (before glucose administration), 30, 60 and 120 minutes after administration. Glucose
levels were measured with glucometer (ContourTS, Bayer, Germany, test stripes: ContourTS,
Ascensia Diabetes care Poland Sp. z o.o., Poland, REF:84239666). The area under the curve
(AUC) was calculated using the trapezoidal rule.
Insulin tolerance test. Insulin tolerance was tested on the next day after the glucose toler-
ance test. Mice had free access to standard food and water, but 3h before insulin tolerance test
the food was taken away. Insulin (0.5 IU/kg b.w.) was injected ip and blood samples were col-
lected at the time points: 0, 15 and 30 minutes from the tail vein and glucose levels were mea-
sured with glucometer (ContourTS, Bayer, Germany, test stripes: ContourTS, Ascensia
Diabetes care Poland Sp. z o.o., Poland, REF:84239666) [50, 51]. The AUC was calculated
using the trapezoidal rule.
Plasma levels of IL-6, TNF-α, CRP and AlaT activity. On the next day after insulin tol-
erance test, 20 minutes after ip administration of heparin (2500 units/mice) animals were sac-
rificed by decapitation. The blood was collected and then centrifuged at 600 x g (15 min, 4˚C)
in order to obtain plasma. To determine AlaT activity in the plasma samples, standard enzy-
matic spectrophotometric test (Biomaxima S.A. Lublin, Poland, catalogue number: 1-023-
0150) was used. In order to quantify IL-6 and TNF-α LANCE1Ultra Detection Kits (Perki-
nElmer, Inc, USA, catalogue numbers: TRF1505, TRF1504C/TRF1504M) were used. For the
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determination of CRP standard enzymatic spectrophotometric tests (Shanghai Sunred Biologi-
cal Technology Co., Ltd, China, catalogue number: 201-02-0219) were applied.
Statistical analysis
The obtained results were analyzed using a one-way variance analysis (ANOVA), followed by
a Dunnett post-hoc test, with the significance level set at 0.05 (locomotor activity, AlaT activ-
ity, IL-6 or TNF-α levels,), a two-way variance analysis (ANOVA), followed by a Bonferroni
post-hoc test (changes in body weight) or a Multi-t test (glucose tolerance test, insulin toler-
ance test, spontaneous activity). The results were expressed as the means ± standard error of
the mean (SEM). Graph Pad Prism 6.0 was used for data analysis.
Results
Influence of KD-64 on locomotor activity
Compound KD-64 did not affect spontaneous activity in mice after single intraperitoneal
administration at all tested doses. The results are shown in Fig 2.
Fig 2. Locomotor activity after a single administration of KD-64. Results are mean ± SEM, n = 6. Comparisons were performed using one-way ANOVA
Dunnet’s post hoc test.
https://doi.org/10.1371/journal.pone.0229806.g002
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Influence of KD-64 on carrageenan-induced paw edema in mice
The mouse paw became edematous after the injection of carrageenan, and in the control
group edema reached a peak at 3h (increase by 97.7% of the initial volume). The increase in
paw edema was significantly inhibited by the KD-64 administration at a dose of 5 mg/kg b.w.
as compared to the control group, which was given carrageenan and vehicle only (Fig 3A).
Since the results were comparable to the ones observed in the group receiving ketoprofen, 5
mg/kg b.w. of KD-64 (as an active dose) has been selected for further studies. In the plasma of
mice treated with KD-64 significant decrease in CRP level (similar to the one observed after
ketoprofen administration) was also determined (Fig 3B).
Influence of KD-64 on zymosan A induced peritoneal inflammation and
vascular permeability
The early infiltration of neutrophils measured at 4h after zymosan-induced peritonitis was sig-
nificantly inhibited in the group receiving KD-64 at the dose of 5 mg/ kg b.w. as compared to
the control group, which was given zymosan A alone and leucocytosis was comparable to the
one measured after ketoprofen administration (Fig 4A). CRP concentration in mice plasma was
also decreased in the group receiving KD-64, interestingly levels of CRP after ketoprofen admin-
istration did not change significantly (Fig 4B). The early vascular permeability measured at 30
min after zymosan-induced peritonitis was significantly inhibited in the group receiving KD-64
compared to the control group, which was given zymosan A alone (Fig 4C). After ketoprofen
administration vascular permeability also decreased however it was still significantly higher than
in control group without induced peritoneal inflammation. Thus, in both experiments KD-64
administered at the same dose as ketoprofen exerted stronger effect than reference compound.
Influence of KD-64 on body weight and peritoneal fat
Mice fed with high-fat/sugar diet showed more weight gain throughout the 12-week period of
inducing obesity as compared to the control group. Animals fed with high-fat diet and treated
with KD-64 at the dose of 5 mg/kg b.w. showed significantly less weight gain than mice from
the obese control group, however only during the first week of administration. From the sec-
ond week of KD-64 administration the difference wasn’t significant. Mice from the group
receiving caffeine (50 mg/kg b.w./day, ip) starting from the first week of treatment gained less
weight compared to the control group and at the end of the experiment weighed significantly
less. The results are shown in Fig 5A and 5B. Animals consuming high-fat feed had also signifi-
cantly higher amount of fat in peritonea. The results are shown in Fig 5C.
Influence of KD-64 on plasma IL-6 and TNF-α levels in obese mice
In obese control mice higher plasma levels of IL-6 and TNF-α were observed than in control
standard fed mice. However, they were significantly lowered by the administration of KD-64
for 21 days at the dose of 5 mg/kg b.w./day and were similar to the values observed in control
non-obese mice (Fig 6). Interestingly, caffeine increased the levels of these parameters, and
they were significantly higher not only vs. levels in standard fed control group but also vs.
obese control group.
Influence of KD-64 on AlaT activity in obese mice
Activity of AlaT in plasma of obese mice was significantly higher than in standard diet fed con-
trol mice. Administration of caffeine had no influence on AlaT activity, surprisingly KD-64 at
the tested dose of 5 mg/kg significantly lowered AlaT levels in obese mice (Fig 7).
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Fig 3. Anti-inflammatory effects of the tested compounds in the carrageenan-induced paw edema test. (A)
Changes in the paw volume in 3h after drug administration in relation to the initial volume (before carrageenan
injection). Results are mean ± SEM, n = 8. Comparisons were performed using one-way ANOVA Dunnet’s post hoc
test. � Significant against control mice administered carrageenen; �p<0.05. (B) Concentration of C-reactive protein in
plasma. Results are mean ± SEM, n = 8. Comparisons were performed by t-Student test. � Significant against control
mice, ^ Significant against control mice administered carrageenen; �p<0.05, ^^p<0.01, ^^^p<0.001.
https://doi.org/10.1371/journal.pone.0229806.g003
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Fig 4. Anti-inflammatory effects of the tested compounds in model of zymosan-induced peritonitis in mice. (A)
Neutrophil infiltration during zymosan-induced peritonitis in mice, (B) Concentration of C-reactive protein in
plasma, (C) Vascular permeability. Results are mean ± SEM, n = 8. Comparisons were performed by t-Student test. �
Significant against control mice, ^ Significant against control mice administered zymosan. �,^p<0.05, ��,^^p<0.01,
���p<0.001.
https://doi.org/10.1371/journal.pone.0229806.g004
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Fig 5. Effect of administration of KD-64 or caffeine on body weight and mass of adipose pads. (A) Percent change of body weight
during the administration. (B) Sum of weight changes. (C) Mass of adipose pads. Results are expressed as means ± SEM, n = 8. Multiple
comparisons were performed by two-way ANOVA, Bonferroni’s post hoc (A) or one-way ANOVA Dunnet’s post hoc tests (B, C). ^
Significant against control mice fed fat/sugar diet; � Significant against control mice fed standard diet; ^p<0.05, ^^p<0.01, ���,
^^^p<0.001.
https://doi.org/10.1371/journal.pone.0229806.g005
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Fig 6. Effect of administration of KD-64 or caffeine on TNF-α (A) and IL-6 (B) levels in plasma. Results are
expressed as means ± SEM, n = 8. Comparisons were performed by one-way ANOVA Dunnet’s post hoc test. �
Significant against control mice fed standard diet; ^ Significant against control mice fed fat/sugar diet; �,^ p<0.05, ��,
^^p<0.01.
https://doi.org/10.1371/journal.pone.0229806.g006
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Glucose tolerance and insulin sensitivity after KD-64 treatment of obese
mice
At 30 minutes after glucose load the blood glucose levels of mice in all tested groups receiving
high fat diet were similar and significantly higher as compared to the levels determined in con-
trol standard diet fed mice. At the subsequent time points (60 and 120 minutes after glucose
load) there was no statistical difference observed between glucose blood levels of standard diet
Fig 7. Effect of administration of KD-64 or caffeine on alanine aminotransferase activity in plasma. Results are expressed as means ± SEM, n = 8.
Comparisons were performed by one-way ANOVA Dunnet’s post hoc test. � Significant against control mice fed standard diet, ^ Significant against control
mice fed fat/sugar diet; �,^ p<0.05.
https://doi.org/10.1371/journal.pone.0229806.g007
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fed mice and high fat diet fed mice treated with KD-64 or caffeine. Interestingly, at the last
time point (120 minutes after glucose load) glucose levels determined only in mice treated
with KD-64 compound were similar to the levels observed in control standard diet fed mice
and significantly lower than in control obese mice. Results are shown in Fig 8A. At the same
time, as shown in Fig 8B, the AUC was decreased by KD-64 treatment at the dose of 5 mg/kg
b.w. as compared to both obese control group and group treated with caffeine, however it was
still higher than in control standard diet fed group.
In the insulin test, neither KD-64 nor caffeine affected blood glucose levels, which were
similar in all tested groups (Fig 9).
Influence of KD-64 on spontaneous activity
Compound KD-64 at the tested dose did not affect spontaneous activity in obese mice after a
single ip administration, but spontaneous activity decreased during certain hours after twenti-
eth administration vs. spontaneous activity in control group. Caffeine, on the other hand,
increased spontaneous activity during certain hours after both first and twentieth ip adminis-
tration of the tested dose. The results are shown in Fig 10.
Discussion
The A2 adenosine receptors play an important role in regulation of glucose homeostasis in
both diabetes and obesity, but they also take active part in the inflammatory processes and
these two particular abilities of A2 adenosine receptors were a subject of the presented study.
In the obesity model we have tested activity of the new selective antagonist of A2A adenosine
receptor—compound KD-64 and compared its effect to the known non-selective antagonist of
adenosine receptors—caffeine. Subsequently in two different inflammation models the activity
of KD-64 has been compared to the activity of potent anti-inflammatory agent—ketoprofen.
From the available literature it is known that caffeine—non-selective adenosine A2A recep-
tor antagonist is able to inhibit various obesity-related abnormalities, including low metabo-
lism, adiposity, dyslipidemia, systemic/tissue inflammation, and insulin resistance [52]. Thus,
we began to wonder whether the selective adenosine A2A receptor antagonist may have similar
properties—especially when it comes to inflammation and obesity?
For research, the selective A2A adenosine receptor antagonist KD-64 has been chosen,
which in previous studies, administered at the dose of 5 mg/kg b.w., exerted antiparkinsonian
activity [43]. Preliminary experiments aimed at the determination of spontaneous and anti-
inflammatory activities after a single administration of the tested compound. The purpose of
this study was to select the lowest dose of KD-64 compound that has anti-inflammatory activ-
ity, but simultaneously does not influence spontaneous activity so it can be administered
chronically in the obesity model. In obesity studies it is particularly important that the tested
compounds do not increase activity, which could further contribute to an increase in energy
consumption and an undesirable effect of the psyche—agitation. On the other hand, it is also
important that the tested compounds do not reduce activity, because sedation, for example,
may cause a decrease in food intake and consequently weight loss that could be attributed as a
non-specific effect. Such effect will also be unacceptable in chronic therapy since chronic fast-
ing can be harmful to the body. Therefore, for the safe and effective compounds tested in obe-
sity models and with potential action towards reducing body weight, it is crucial to have no
effect on spontaneous activity [53]. In the case of presented studies, it is especially important
since adenosine, through A1 and A2A receptors, is involved in the regulation of spontaneous
activity [54, 55]. It has been reported that adenosine A2A agonists, e.g. the CGS 21680
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Fig 8. Glucose tolerance test. (A) Intraperitoneal glucose tolerance test (IPGTT), (B) area under the curve of IPGTT.
Results are expressed as means ± SEM, n = 8. Comparisons were performed by Multi-t test. � Significant between
control mice fed standard diet and control mice fed fat/sugar diet, ^ Significant between control mice fed standard diet
and mice fed fat/sugar diet and treated with KD-64, & Significant between control mice fed standard diet and mice fed
fat/sugar diet and treated with caffeine, $ Significant between control mice fed fat/sugar diet and mice fed fat/sugar diet
and treated with KD-64; $p<0.05, ���,^^^,&&&p<0.001.
https://doi.org/10.1371/journal.pone.0229806.g008
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Fig 9. Insulin sensitivity test. (A) Insulin tolerance test (ITT), (B) area under the curve of the ITT. Results are
expressed as means ± SEM, n = 8. Comparisons were performed by Multi-t test.
https://doi.org/10.1371/journal.pone.0229806.g009
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Fig 10. Spontaneous activity after the first (A) and twentieth (B) administration of tested compounds. Results are
expressed as means ± SEM, n = 8. Comparisons were performed by Multi-t test. � Significant between control mice fed
fat/sugar diet and mice fed fat/sugar diet and treated with KD-64, # Significant between control mice fed fat/sugar diet
and mice fed fat/sugar diet and treated with caffeine; �,#p<0.05, ��,##p<0.01.
https://doi.org/10.1371/journal.pone.0229806.g010
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compound, can cause sedation [56], while antagonists of this receptor, e.g. caffeine, have a
stimulating effect [57].
Our research showed that the selective A2A receptor antagonist KD-64 did not induce
changes in spontaneous activity after a single administration therefore we proceeded with the
further experiments. In models of both local and systemic inflammation the anti-inflammatory
effect of the KD-64 compound administered at a dose of 5 mg/kg b.w./day was comparable to
the anti-inflammatory effect of ketoprofen (5 mg/kg b.w./day) used as a reference standard.
There are reports in the literature that pharmacological blockade of selected adenosine recep-
tor subtypes (PSB-36, PSB-1115, MSX-3, and PSB-10) after systemic application of antagonists
generally leads to decrease in edema formation after the carrageenan injection [58]. In the case
of A2A antagonist, activity of the drug varies with time, suggesting that the importance of aden-
osine receptor activation in the inflammatory process dynamically changes in the course of
inflammation [58]. The local injection of the highly A2A-selective agonist CGS21680 induced
paw edema, conversely [59] A2A antagonist MSX-3, at a dose of 10 mg/kg b.w., significantly
reduced the carrageenan-induced edema [58]. Similarly, in our study, we showed that intra-
peritoneal injection of selective A2A receptor antagonist KD-64 at a dose of 5 mg/kg b.w./day,
results in a potent inhibition of carrageenan-induced edema formation (Fig 3). Thus, the
results obtained are in line with literature reports and clearly show that selective A2A receptor
antagonists have anti-inflammatory effect.
Adenosine may be added to the growing list of key signalling molecules that regulate vascu-
lar function and homeostasis and to a very selected list of agonists that promote integrity of the
vascular bed [60]. There are reports in the literature that adenosine regulates the pulmonary
endothelial cells barrier function via A2A receptors [60] and through its influence on the aden-
osine receptors A1 and A2A can modulate for example blood-brain barrier permeability [61].
Blocking just the adenosine A2A receptor reduces permeability and blocks the entry of inflam-
matory cells and soluble factors into the brain [61]. 1It has been also reported that vascular
permeability in the hind plantar skin of rats decreases following lumbar sympathectomy, pos-
sibly via reduction of adenosine receptor A2A expression [62]. In the second model of inflam-
mation used in the presented study i.e. zymosan-induced peritonitis, KD-64 showed
significant anti-inflammatory effect, manifested by decrease of both vascular permeability, and
plasma neutrophils count. The results were comparable to the ones obtained after ketoprofen
administration. It is an important finding, confirming that A2A adenosine receptor blockade
may be directly responsible for a decrease in vascular permeability.
Anti-inflammatory effect of KD-64 was also evaluated through the measurement of CRP
levels—an acute phase protein primarily expressed and secreted by the liver. In response to tis-
sue injury or infection, the plasma concentrations of CRP can increase rapidly, moreover CRP
level also increases in chronic inflammatory diseases, including cardiovascular and autoim-
mune disease. Due to the correlation between CRP and inflammation, CRP has attracted wide
attention as a non-specific marker used for purpose of evaluation and monitoring of the infec-
tion and inflammation development as well as a prognostic marker for cardiovascular events
[63]. In both models of inflammation, the tested antagonist of A2A adenosine receptors KD-64
statistically significantly reduced the level of CRP in plasma. This confirms the anti-inflamma-
tory efficacy of this compound after its ip administration at a dose of 5 mg/kg b.w./day.
Based on the described above findings the dose of 5 mg/kg b.w./day of KD-64 was selected
for testing in mice obesity model. During the first days of KD-64 administration, obese ani-
mals weighed significantly less compared to the obese control mice. But then they began to
gain weight at the rate comparable to obese control mice. Not surprisingly, the amount of peri-
toneal adipose tissue, measured at the end of the experiment, was comparable in these two
groups of animals. It is interesting, however, that the group receiving caffeine at a dose of 50
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mg/kg/ b.w./day which gained weight significantly less than obese control mice (results consis-
tent with the literature findings) [64] at the end of the experiment had the amount of perito-
neal fat also comparable to the other experimental groups.
As the compound KD-64 was administered, its effectiveness in reducing weight of obese
mice was decreasing. Unfortunately, the conducted research does not provide an assessment
of why this might have happened. More detailed investigation is needed to determine if, for
example, it was due to changes in the number and sensitivity of adenosine receptors with
repeated administrations. Literature reports such cases that repeated administrations of adeno-
sine A2A ligands may lead to the changes in regulation (both up- or down-regulation) of the
A2A adenosine receptor gene [65]. In addition, various pathological conditions can cause
changes in the density of A2A adenosine receptors, for example it has been shown that pro-
inflammatory stimuli up-regulate A2A adenoside receptor and for the effective treatment
appropriately higher doses of ligands are required [66]. A reduction in DNA methylation at
the A2A adenosine receptor gene promoter site and an increase in the protein levels and gene
expression in binge-like-eating rats has been also reported [65]. Interestingly, alterations of
DNA methylation of A2A adenosine receptor has been observed in other diseases such as
schizophrenia [67], Huntington’s disease [68] and cardiomyopathies [69].
Studies of spontaneous activity in obese mice showed that repeated administration of KD-
64 led to a decrease in spontaneous activity at some hours after the twentieth administration of
this compound. As previously mentioned, adenosine A2A agonists, e.g. the CGS 21680 com-
pound, can cause sedation [56], which may indicate that in fact a change in receptor density
and sensitivity (up-regulation) after repeated administration of KD-64 could be the cause of
such observation.
In obesity, the white adipose tissue produces large numbers of inflammatory agents includ-
ing TNF-α and IL-6, which can affect the physiology of the adipose tissue locally, but also may
induce systemic effects on the other organs [70]. IL-6 has emerged as one of the mediators
linking obesity-derived chronic inflammation with insulin resistance. In high fat diet fed obese
mice, activated hepatic IL-6 signalling is accompanied by systemic and local insulin resistance,
which can be reversed by neutralization of IL-6 [52]. Indeed, in our study, the levels of TNF-α
and IL-6 in the plasma of obese mice were higher as compared to control non-obese mice and
were significantly reduced by the administration of KD-64. This reduction in the levels of
inflammatory cytokines is probably the result of the anti-inflammatory effect of the tested
compound. It should be emphasized that these tests were made with homogeneous, very sensi-
tive and reliable methods. In addition, in the glucose load test, significant differences were
observed in the response curve in group which received KD-64 treatment compared to the
obese control group. The glucose level in mice treated with KD-64 one hour after loading did
not differ statistically from the level determined in non-obese mice fed standard feed. This
indicates an improvement in glucose tolerance in KD-64-treated mice compared to the obese
control mice which might be connected to the anti-inflammatory effect of the tested com-
pound and a decrease in plasma IL-6 levels, since IL-6 and its signalling path play complex
roles in metabolic disorders [71]. It was recently reported that IL-6 enhances fatty acid synthe-
sis in murine hepatocytes via the induction of the citrate transporter mIndy [72] and it also
exacerbates hepatic inflammation and steatosis [73]. Additionally, adenosine has been shown
to promote IL-6 production [74] and our study demonstrates that adenosine A2A receptor may
be associated with this activity, because selective antagonist of this particular receptor
decreased IL-6 level in plasma. In contrast, several human studies reported that despite the
well-proven anti-inflammatory effect of caffeine [75, 76, 77], its administration, leads to an
increase in serum IL-6 levels [78, 79]. The results of our study, even though performed on
mice, are in line with these observations. Observed in our studies differences in plasma IL-6
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levels between the caffeine and KD-64 treatment groups may indicate that decrease in IL-6
concentration is due not only to the anti-inflammatory effect of the KD-64 compound, but
also adenosine A2A receptor blockade. This is an interesting topic that undoubtedly requires
further research.
Another interesting and very favourable result of KD-64 treatment is its ability to normalize
the elevated AlaT activity, induced by high-fat/sugar feeding. Liver is a vital organ involved in
detoxification and drug metabolism, therefore potential hepatotoxicity could eliminate the test
compound from further stages of development especially if it is intended for longer use. In our
experiment caffeine did not have any effect on AlaT levels, although there are reports in the lit-
erature that in the obesity model caused by the administration of high-fat feed, caffeine admin-
istered for several weeks at the dose of 20–40 mg/kg in the drinking water normalizes liver
enzymes [64]. Probably this effect depends also on the dose and time of caffeine
administration.
In conclusion, after repeated administrations of a selective A2A adenosine receptor antago-
nist compound KD-64 with documented anti-inflammatory activity, no significant reduction
in weight gain was observed in obese mice fed high-calorie feed. However, contrary to caffeine
(non-selective adenosine receptor antagonist) investigated compound normalized levels of
selected cytokines and inflammatory proteins, including IL-6, as well as, activity of alanine
transaminase and improved glucose tolerance in the obese mice. Thus our findings prove that
the activity of the selective adenosine A2A receptor antagonist is different from that of the non-
selective antagonist.
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G. Reduced Systemic levels of IL-10 are associated with the severity of obstructive sleep apnea and
insulin resistance in morbidly obese humans. Mediators Inflamm. 2015; 2015:493409. https://doi.org/
10.1155/2015/493409 PMID: 25944984
11. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J
Nutr. 2004; 92:347–355. https://doi.org/10.1079/bjn20041213 PMID: 15469638
12. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endo-
plasmic reticulum and metabolic disease. J Lipid Res. 2007; 48:1905–1914. https://doi.org/10.1194/jlr.
R700007-JLR200 PMID: 17699733
13. Nathan C. Epidemic inflammation: pondering obesity. Moi Med. 2008; 14:485–492.
14. Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological
alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other
pathophysiological consequences: An update on glucose toxicity. Biomed and Pharmac. 2018;
107:306–328
15. Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets—what are the challenges?
Nat Rev Drug Discov. 2013; 12:265–86. https://doi.org/10.1038/nrd3955 PMID: 23535933
16. Cully M. Obesity: Adenosine protects from diet-induced obesity. Nat Rev Drug Discov. 2014; 13:886–
887.
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